Table 4.
Clinical trials for mRNA vaccine delivery (COVID-19 vaccines are not included).
| Drug | Disease | Administration route | Lipid-based carriers | Trial phase | Ref. |
|---|---|---|---|---|---|
| Core-g28v2 60mer and eOD-GT8 60mer | HIV | im | LLPs | Ⅰ (NCT05001373) | https://clinicaltrials.gov/ct2/show/NCT05001373 |
| CV7202 | Rabies | im | LLPs | Ⅰ (NCT03713086) | https://clinicaltrials.gov/ct2/show/NCT03713086 |
| GSK 692342 | Tuberculosis | im | LLPs | Ⅱ (NCT01669096) | https://clinicaltrials.gov/ct2/show/NCT01669096 |
| mRNA-1010 | Seasonal influenza | im | LLPs | Ⅰ/Ⅱ (NCT04956575) | https://clinicaltrials.gov/ct2/show/NCT04956575 |
| mRNA-1325 | Zika virus | – | LLPs | Ⅰ (NCT03014089) | https://clinicaltrials.gov/ct2/show/NCT03014089 |
| mRNA-1345 | Respiratory syncytial virus | im | LLPs | Ⅰ (NCT04528719) | https://clinicaltrials.gov/ct2/show/NCT04528719 |
| mRNA-1440 | Influenza H10N8 | im | LLPs | Ⅰ (NCT03076385) | https://clinicaltrials.gov/ct2/show/NCT03076385 |
| mRNA-1653 | Human metapneumovirus and human parainfluenza infection | im | LLPs | Ⅰ (NCT03392389) | https://clinicaltrials.gov/ct2/show/NCT03392389 |
| mRNA-1647 | Cytomegalovirus infection | im | LLPs | Ⅱ (NCT04232280) | https://clinicaltrials.gov/ct2/show/NCT04232280 |
| mRNA-1851 | Influenza H9N9 | im | LLPs | Ⅰ (NCT03345043) | https://clinicaltrials.gov/ct2/show/NCT03345043 |
| mRNA-1893 | Zika virus | im | LLPs | Ⅰ (NCT04064905) | https://clinicaltrials.gov/ct2/show/NCT04064905 |
| VAL-181388 | Chikungunya virus | im | LLPs | Ⅰ (NCT03325075) | https://clinicaltrials.gov/ct2/show/NCT03325075 |
| RG-SAM | Rabies | im | LLPs | Ⅰ (NCT04062669) | https://clinicaltrials.gov/ct2/show/NCT04062669 |
| BI 1361849 | Metastatic non-small cell lung cancer | intratumoral injection | LLPs | Ⅰ/Ⅱ (NCT03164772) | https://clinicaltrials.gov/ct2/show/NCT03164772 |
| BNT113 | Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer | iv | LPs | Ⅱ (NCT04534205) | https://clinicaltrials.gov/ct2/show/NCT04534205 |
| HARE-40 | Squamous cell carcinoma, head and neck neoplasm, cervical neoplasm, penile neoplasms malignant | id | LLPs | Ⅰ/Ⅱ (NCT03418480) | https://clinicaltrials.gov/ct2/show/NCT03418480 |
| Lipo-MERIT | Melanoma | iv | LLPs | Ⅰ (NCT02410733) | https://clinicaltrials.gov/ct2/show/NCT02410733 |
| mRNA-2416 | Relapsed/refractory solid tumor malignancies or lymphoma, ovarian cancer | intratumoral injection | LLPs | Ⅰ/Ⅱ (NCT03323398) | https://clinicaltrials.gov/ct2/show/NCT03323398 |
| mRNA-2752 | Relapsed/refractory solid tumor malignancies or lymphoma | intratumoral injection | LLPs | Ⅰ (NCT03739931) | https://clinicaltrials.gov/ct2/show/NCT03739931 |
| mRNA-4157 | Melanoma | im | LLPs | Ⅱ (NCT03897881) | https://clinicaltrials.gov/ct2/show/NCT03897881 |
| mRNA-4650 | Melanoma, colon cancer, gastrointestinal cancer, genitourinary cancer, hepatocellular cancer | im | LLPs | Ⅰ/Ⅱ (NCT03480152) | https://clinicaltrials.gov/ct2/show/NCT03480152 |
| mRNA-5671/V941 | Non-small-cell lung carcinoma, pancreatic neoplasms, colorectal neoplasms | im | LLPs | Ⅰ (NCT03948763) | https://clinicaltrials.gov/ct2/show/NCT03948763 |
| RNA-LPs | Adult glioblastoma | iv | LPs | Ⅰ (NCT04573140) | https://clinicaltrials.gov/ct2/show/NCT04573140 |
| RO7198457 | Advanced melanoma | iv | LLPs | Ⅱ (NCT03815058) | https://clinicaltrials.gov/ct2/show/NCT03815058 |
| RO7198457 | Melanoma, non-small-cell lung cancer, bladder Cancer, colorectal cancer, triple negative breast cancer, renal cancer, head and neck cancer and other solid Cancers | iv | LLPs | Ⅰ (NCT03289962) | https://clinicaltrials.gov/ct2/show/NCT03289962 |
| SAR441000 | Metastatic neoplasm | intratumoral injection | LLPs | Ⅰ (NCT03871348) | https://clinicaltrials.gov/ct2/show/NCT03871348 |
| TNBC-MERIT | Triple negative breast cancer | iv | LPs | Ⅰ (NCT02316457) | https://clinicaltrials.gov/ct2/show/NCT02316457 |
| W_ova1 | Ovarian cancer | iv | LPs | Ⅰ (NCT04163094) | https://clinicaltrials.gov/ct2/show/NCT04163094 |
| ARCT-810 | Ornithine transcarbamylase deficiency | iv | LLPs | Ⅰ (NCT04442347) | https://clinicaltrials.gov/ct2/show/NCT04442347 |
| Low Density Lipoprotein Receptor mRNA Exosomes | Familial hypercholesterolemia | iv | Exosomes | Ⅰ (NCT05043181) | https://clinicaltrials.gov/ct2/show/NCT05043181 |
| mRNA-3927 | Propionic acidemia | iv | LLPs | Ⅰ/Ⅱ (NCT05130437) | https://clinicaltrials.gov/ct2/show/NCT05130437 |
| UXO053 | Glycogen storage disease type III | iv | LLPs | Ⅰ/Ⅱ (NCT04990388) | https://clinicaltrials.gov/ct2/show/NCT04990388 |
| mRNA-6231 | Various autoimmune disorders | sc | LLPs | Ⅰ (NCT04916431) | https://clinicaltrials.gov/ct2/show/NCT04916431 |
‒, not applicable.
Id, intradermal injection; im, intramuscular injection; iv, intravenous injection; LPs, liposomes; LLPs, liposome-like nanoparticles; sc, subcutaneous injection.